Clinical benefit of two-times-per-day aclidinium bromide compared with once-a-day tiotropium bromide hydrate in COPD: a multicentre, open-label, randomised study.

ABSTRACT:

Objective

Chronic obstructive pulmonary disease (COPD) is mainly treated pharmaceutically with bronchodilators. The purpose of this study was to evaluate the clinical benefits of two-times-per-day aclidinium bromide (Acli-BID) compared with once-a-day tiotropium bromide hydrate (Tio-QD) in patients with COPD.

Design

This study was a multicentre, open-label, randomised study.

Setting

Fourcentres in Kagawa prefecture, Japan.

Participant

Patients who were diagnosed to have COPD Grade 2-3 according to the Global Initiative for Chronic Obstructive Lung Disease 2015 criteria were enrolled.

Interventions

Patients were randomly assigned to receive Acli-BID or Tio-QD at a 1:1 ratio, and followed for 8 weeks. Acli-BID was administered in the morning and night, and

SUBMITTER: Kamei T 

PROVIDER: S-EPMC6661652 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature